sclc239861_S78.txt
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.440
- MITOTIC_SPINDLE+0.390
- PI3K_AKT_MTOR_SIGNALING+0.390
- PROTEIN_SECRETION+0.320
- MTORC1_SIGNALING+0.310
- HYPOXIA+0.300
- MYC_TARGETS_V1+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- DNA_REPAIR+0.290
Top 10 suppressed
- COAGULATION-0.240
- KRAS_SIGNALING_DN-0.240
- MYOGENESIS-0.230
- CHOLESTEROL_HOMEOSTASIS-0.220
- XENOBIOTIC_METABOLISM-0.210
- ESTROGEN_RESPONSE_LATE-0.200
- NOTCH_SIGNALING-0.200
- WNT_BETA_CATENIN_SIGNALING-0.150
- ANGIOGENESIS-0.140
- ESTROGEN_RESPONSE_EARLY-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.845 |
| 2 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.844 |
| 3 | TCGA-DK-AA6R-01A-11R-A42T-07 | — | — | 0.812 |
| 4 | TCGA-78-7146-01A-11R-2039-07 | — | cohortA1 | 0.812 |
| 5 | TCGA-CV-7434-01A-11R-2132-07 | — | — | 0.810 |
| 6 | SRR650153 | — | — | 0.807 |
| 7 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.807 |
| 8 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.806 |
| 9 | SRR934964 | — | — | 0.806 |
| 10 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |